The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

Its lead candidates treat solid tumors, non-small cell lung cancer (NSCLC) and brain metastases. The company works in collaboration with contract research organizations (CROs), medical institutions ...

Teos Therapeutics (ITOS) announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Getting a diagnosis of lung cancer can be scary, especially when you don't know what to expect. To help, experts will guide ...

Nuvalent, Inc. has promising drugs, zidesamtinib and NVL-655, targeting NSCLC with encouraging data. Read why NUVL stock is a ...

NovoCure's TTFields therapy, combined with standard chemotherapy, improves overall survival in advanced pancreatic cancer.

In a Phase III clinical trial, a therapy known as Tumor Treating Fields (TTFields) increased survival for patients whose ...

Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, recent research showed. A novel intratumoral treatment was administered to the first ...

There is no sure way to prevent lung cancer but you can reduce the risk of it by not smoking. You can reduce your children’s ...